United Therapeutics

United Therapeutics Corporation is a biotechnology company dedicated to developing and commercializing innovative therapies for patients with chronic and life-threatening conditions. The company has four approved products, primarily targeting pulmonary arterial hypertension (PAH), a rare and progressive disease characterized by elevated blood pressure in the lung arteries. United Therapeutics focuses on the prostacyclin pathway in its PAH treatments, many of which are based on the molecule treprostinil. Although most of its sales are generated in the United States, the company is committed to expanding its reach globally. In addition to its PAH therapies, United Therapeutics also markets a pediatric oncology drug, while maintaining a strong emphasis on addressing the unmet medical needs associated with pulmonary arterial hypertension and other complex health challenges.

James Edgemond

CFO and Treasurer

9 past transactions

BETA Technologies

Series C in 2024
BETA Technologies is an electric aerospace company focused on developing electric aircraft and advanced flight control systems aimed at promoting clean aviation technology. The company designs a self-sufficient ecosystem of electric vertical takeoff and landing (eVTOL) aircraft that meets the transportation needs of people and goods while adhering to environmental principles. BETA's technology encompasses all-electric aircraft and a comprehensive charging infrastructure to support various electric vehicles, enhancing the efficiency and sustainability of transportation. The company also offers training programs for pilots and maintenance personnel, serving clients in cargo, passenger, and emergency response sectors, thereby enabling more efficient, cleaner, and faster transportation solutions.

SteadyMed Therapeutics

Acquisition in 2018
SteadyMed Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapeutic product candidates. Based in San Ramon, California, with a research and development center in Rehovot, Israel, the company offers a unique delivery platform known as PatchPump, which is a customizable, pre-filled, and pre-programmed disposable device designed for large volume and viscous formulations. Among its key products is Trevyent, a single-use PatchPump pre-filled with treprostinil for the treatment of pulmonary arterial hypertension. SteadyMed also develops SMT-201 for the subcutaneous delivery of Ketorolac, a non-steroidal anti-inflammatory drug, and SMT-301 to deliver bupivacaine directly into surgical wound areas for localized pain relief. The company's innovative approach aims to enhance the delivery of injectable therapeutic drugs, addressing various medical needs such as pain management and chronic conditions.

Celularity

Venture Round in 2018
Celularity is a clinical-stage biotechnology company focused on advancing cellular medicine through the development of off-the-shelf placental-derived allogeneic cell therapies. Its product pipeline includes unmodified and genetically modified natural killer (NK) cells, CAR-engineered T cells, and mesenchymal-like adherent stromal cells. The company targets various health conditions, including cancer, immunologic disorders, infectious diseases, and degenerative illnesses. Celularity leverages the unique biology of the placenta, aiming to create effective and accessible therapies to address significant unmet medical needs. In addition to its cell therapy initiatives, Celularity operates a bio-banking segment, which contributes substantially to its revenue.

University of Alabama at Birmingham

Grant in 2016
The University of Alabama at Birmingham (UAB), established in 1969, is a distinguished institution located in Birmingham, Alabama. It offers a diverse range of over 130 undergraduate and graduate programs, including degrees in the arts, sciences, business, education, engineering, and public health. UAB is particularly renowned for its medical school, which encompasses one of the largest university medical centers in the United States. The university has produced numerous scholars and award recipients, such as Fulbright, Rhodes, and Truman scholars, reflecting the high caliber of its education. Student life at UAB is dynamic, featuring more than 150 student organizations, an active Greek community, and a top-ranking recreation and fitness center, alongside year-round intramural sports. Most students reside in on-campus housing, and UAB provides financial aid and departmental fellowships to support those in need of tuition assistance. Through its commitment to education, research, and community service, UAB addresses both local and global challenges while fostering a culture of discovery and innovation.

Revivicor

Acquisition in 2011
Revivicor is a regenerative medicine company that specializes in xenotransplantation, utilizing advanced animal biotechnology to create human-compatible organs from gene-edited pigs. The company's innovative approach aims to address the critical shortage of human organs available for transplant, providing a high-quality, alternative tissue source for treating degenerative diseases in humans. By leveraging its cutting-edge platforms, Revivicor seeks to enhance the field of regenerative medicine and improve patient outcomes through viable organ alternatives.

Transoma Medical

Series D in 2008
Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

Medicomp

Acquisition in 2000
Medicomp specializes in the development and manufacturing of advanced ambulatory heart-monitoring systems, catering to the cardiac telemedicine and home sleep testing sectors. The company employs innovative diagnostic technologies and Diogenes algorithms to deliver comprehensive beat-to-beat analyses of the P-wave, as well as assessments of heart rate, rhythm, and QRS morphology. In addition to its monitoring systems, Medicomp provides patient reports, remote monitoring capabilities, and integration with electronic medical records, ensuring a seamless experience for healthcare providers and patients alike.

Cooke Pharma

Acquisition in 2000
Cooke Pharma is a privately held company and is the exclusive maker of the HeartBar line of arginine-enriched products.

SynQuest

Acquisition in 1999
SynQuest, Inc. is a company that manufactured treprostinil, the bulk active ingredient in Remodulin.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.